Protara’s TARA-002 Cell Therapy Shows Exceptional Promise in Treating Non-Muscle Invasive Bladder Cancer

Efficacy:
TARA-002 demonstrated a 72% six-month complete response rate across BCG exposures in the Phase 2 ADVANCED-2 trial for NMIBC patients12.

BCG-Unresponsive Patients:
100% six-month complete response rate was observed in BCG-Unresponsive patients, indicating significant efficacy in this difficult-to-treat population12.

BCG-Naïve Patients:
64% six-month complete response rate was observed in BCG-Naïve patients, showing broad applicability of TARA-00212.

Reinduction Salvage Rate:
An 80% reinduction salvage rate was noted, with 100% of patients maintaining complete response from three to six months12.

Safety Profile:
The therapy showed a favorable safety profile with no Grade 2 or greater treatment-related adverse events, making it a potentially transformative treatment option12.

Market Impact:
The positive results led to a significant increase in Protara Therapeutics' stock price, nearly doubling its value4.

Sources:

1. https://www.stocktitan.net/news/TARA/protara-announces-positive-results-from-the-ongoing-phase-2-advanced-uz2t2xyowihh.html

2. https://ir.protaratx.com/news-releases/news-release-details/protara-announces-positive-results-ongoing-phase-2-advanced-2

4. https://endpts.com/protaras-stock-nearly-doubles-as-biotech-divulges-new-bladder-cancer-data/